Amyloidosis secondary to intrapulmonary Castleman disease mimicking pulmonary hyalinizing granuloma-like clinical features

A rare case report

Shao-Ting Wang, MDa,*, Qi-Pu Wang, MDb, Ji Li, MAc, Ting Zhang, MDa,*, Lu Zhang, MDb, Yue-Ying Mao, MDd

Abstract

Rationale: Amyloidosis secondary to intrapulmonary Castleman disease (CD) is a rare benign disease diagnosed by histopathology. It seems to be associated with chronic inflammation, and large amounts of IL-6 produced in the germinal center of CD may enhance the production of precursor of amyloid.

Patient concerns: We reported a case of an 18-year-old woman presenting with dry cough and dyspnea on exertion for 6 months and detailed exams revealed multiple pulmonary nodules, positive antinuclear antibodies, hypocomplementemia, and thrombocytopenia.

Diagnoses: A computed tomography-guided percutaneous lung biopsy revealed the histopathological features of pulmonary hyalinizing granuloma (PHG), but video-assisted pulmonary wedge resection for biopsy with immunohistochemical stains finally demonstrated a corrected diagnosis of intrapulmonary CD with secondary amyloidosis.

Interventions: The patient had received prednisone and Tacrolimus for 6 months.

Outcomes: There was no significant improvement in pulmonary lesions or platelet level. Chemotherapy to CD was needed.

Lessons: Intrapulmonary CD should be considered in patients with multiple pulmonary nodules responsive to corticosteroid and diagnosis of PHG should be carefully considered based on small lung biopsy sample. The treatment of amyloidosis secondary to CD remains to be uncertain.

Abbreviations: CD = Castleman disease, PHG = pulmonary hyalinizing granuloma.

Keywords: Castleman disease, pulmonary hyalinizing granuloma, secondary amyloidosis

1. Introduction

Castleman disease (CD), also called angiofollicular lymph node hyperplasia, is an uncommon disease of unknown etiology and intrapulmonary CD has been reported in a few cases. In 1980, Plavnick et al reported systemic amyloidosis with CD. The condition is fairly rare that intrapulmonary CD can mimic tumor or even metastatic adenopathy. In this case, a female patient presenting with multiple pulmonary nodules developed amyloidosis secondary to intrapulmonary CD, and was misdiagnosed as pulmonary hyalinizing granuloma (PHG) previously. In the patient, preoperative diagnosis was difficult and repeated invasive attempts, especially surgical biopsy was required for pathological diagnosis.

2. Case report

An 18-year-old female student was referred to our hospital presented with dry cough and dyspnea on exertion for 6 months. The patient denied fever, hemoptysis, weight loss, or tobacco use. Past medical history included immune thrombocytopenia for 3 years before the visit, for which she received 1.5 years of oral glucocorticoid. Laboratory examinations revealed iron deficiency anemia (hemoglobin = 90 g/L), platelet count of 6 × 10^11/L, and total white cell count of 4.4 × 10^9/L. Urinalysis, liver function, electrolytes, and creatinine were within normal ranges. Her erythrocyte sedimentation rate (>140 mm/h), C-reactive protein (150.1 mg/L), and serum IL-6 (7.3 pg/mL), IL-8 (279 pg/mL), tumor necrosis factor-α (175.0 pg/mL), tumor necrosis factor-α (175.0 pg/mL) were significantly elevated. Serum measurement of immunoglobulins showed elevated total IgG of 27.59 g/L, while serum IgG4, M protein, serum, and urine immunofixation electrophoresis and light chain were negative or normal. Hypocomplementemia (C4 = 0.079 g/L),
positive antinuclear antibodies (titer 1:160), and positive Coombs test were found. Additional clinically relevant autoantibodies, (1–3)-β-D-glucan, galactomannan, interferon gamma release assay, and tumor markers were negative or normal. Pulmonary function tests revealed restriction and decreased diffusing capacity with forced vital capacity of 2.05 L (65.9% predicted), total lung capacity of 2.83 L (68.9% predicted) and diffusing capacity for carbon monoxide of 28.8% predicted. Chest computed tomography (CT) showed multiple well-defined nodules randomly distributed in both lung fields and mediastinum lymphadenopathy, with no significant pleural effusion (Fig. 1). Bronchoscopy demonstrated no endobronchial pathological lesions, and a culture of bronchoalveolar lavage fluid showed no evidence of tuberculosis or fungal infection. Cytological evaluation was negative for malignant cells. A CT-guided percutaneous lung biopsy was performed, and histopathological examinations revealed some defining features for hyalinizing granuloma, including homogenous hyaline lamellae around small blood vessels and dense infiltrates of lymphocytes, plasma cells with frequent lymph follicle formation (Fig. 2). The patient was diagnosed with PHG, and received prednisone 1 mg/kg/d and tacrolimus. Unfortunately, 6 months after initiation of therapy with prednisone gradually tapered, neither pulmonary lesions nor platelet level revealed remarkable interval change. As detailed investigations in clinic failed to uncover any more underlying condition, the patient underwent video-assisted pulmonary wedge biopsy.

Intraoperatively, multiple white and tough-elastic nodules were found in the upper and lower lobes of lung, partially fused to mass, with pulmonary parenchyma edema surrounded. One isolated lesion was dissected from the left upper lobe, which contained 2 nodules. The diameters of nodules were 1 and 2 cm, and specimens were sent for microorganism culture and pathological examination, respectively. Microorganism culture was negative. Pathologic exam revealed nodular interstitial pink deposits in lungs which stained pink with hematoxylin and eosin, and pathologic examination also showed lymph node hyperplasia and follicular architecture along broncho vascular bundle and

**Figure 1.** Chest CT showing multiple bilateral lung nodules. CT = computed tomography.
under the pleura, with plasma cell infiltration (Fig. 3a). On immunohistochemical stains, the hyperplastic cells were positive for CD20 (follicle), CD138 and negative for CD3, IgG, and IgG4. Congo-red, alcoholized Congo-red (Fig. 3b), alkaline Congo-red stains, and kappa and lambda light chain immunostains were positive. Histological evaluation demonstrated a revised diagnosis of intrapulmonary CD with secondary amyloidosis. Human herpesvirus-8 (HHV-8) was tested to be negative.

3. Discussion

CD has been described as a lymphoproliferative disorder that features benign hyperplasia of the lymph nodes, and the etiology is not known with certainty. The plasma cell type and the mixed type are accompanied with various systemic manifestations, such as fever, weight loss, anemia, splenomegaly, peripheral lymphadenopathy, hypoalbuninemia, hypergammaglobulinemia, and increased levels of acute-phase proteins. In 2017, an international panel established the first ever diagnostic criteria for idiopathic multicentric Castleman disease (iMCD), which was HHV-8-negative, and the criteria required multicentric lymphadenopathy with defined histopathology, ≥2 clinical/laboratory changes, and exclusion of iMCD mimics. The recently described “TAFRO syndrome” identifies a subset of iMCD patients with shared manifestations, including thrombocytopenia, anasarca/ascites, reticulin fibrosis in bone marrow, renal dysfunction, organomegaly (TAFRO), while iMCD patients without TAFRO syndrome typically have thrombocytosis, hypergammaglobulinemia, and less severe fluid accumulation. The relationship between CD and secondary amyloidosis was reported before, and most cases revealed amyloid deposits in kidney. Secondary amyloidosis is believed to be caused mainly by chronic inflammation, and large amounts of IL-6 produced in the germinal center of CD may enhance the production of precursor of amyloid. Intrapulmonary CD is exceedingly rare, and differential diagnosis includes all types of tumors, like lung carcinoma, carcinoid tumors, hamartochondroma, lymphoma, or metastases. While our patient was misdiagnosed as PHG previously, PHG is a rare benign disease and respiratory manifestations were reported such as cough, chest pain, dyspnea, and hemoptysis. Extrapulmonary fibrous lesions, including skin, pharynx, pleural, pericardium, liver, may accompany PHG. About 70% of patients present with multiple lung nodules, sometimes with calcification and cavity, and F-18-fluorodeoxyglucose positron emission tomography can reveal hypermetabolic activity in PHG lesions. PHG seems to be associated with autoimmune diseases with some serologic evidences, and infection and lymphoproliferative disorders are also assumed to be the cause. Corticosteroids and immunosuppressive drug were effective in some cases. Whether PHG represents a specific pathologic diagnosis or a clinicopathologic entity remains to be explored. PHG is diagnosed based on histopathology, which is characterized by a central area of whorled hyalinized collagen lamellae surrounded by lymphocytes, plasma cells, and histiocytes, but the diagnosis of PHG based on the needle biopsy might be questionable. Our patient, that the diagnosis of CD and secondary amyloidosis was unclear until the histopathological examination of the resected lymphoid tissue, and fulfilled the diagnostic criteria of iMCD. In agreement with previous reports, bronchoscopy or a pulmonary fine needle biopsy might not provide a definitive diagnosis of CD, and surgical resection and immunostains were finally needed. The therapeutic effect of corticosteroid with tacrolimus was poor for our patient. Untreated systemic amyloidosis often has an unrelenting clinical course, and the treatment of amyloidosis secondary to CD is presently unknown. There has been a steady
increase in survival with secondary reactive amyloidosis in treatment strategies for underlying inflammatory disorders. Complete surgical resection was proposed to be the best treatment for unicentric CD. However, the role of surgery in multicentric disease is limited, and the efficacy of systemic therapy, such as radiotherapy, steroids alone, or together with antineoplastic chemotherapy, even humanized anti-IL-6 receptor monoaibody, is uncertain.

This case illustrates the clinical features of intrapulmonary CD with secondary amyloidosis mimicking PHG. The limitations in approach to this study is etiology, physiopathology, and treatment of amyloidosis secondary to CD remain to be further investigated and the patient needed longer follow-up.

Author contributions
STW and QPW designed the case report and were major contributors in writing the manuscript, they contributed equally to this work. JL acquired and interpreted the patient’s pathological data. TZ collected the patient clinical data. LZ and YYM checked the bone marrow smear of patient. JHS reviewed and revised the manuscript.

Data curation: Qi-Pu Wang, Ting Zhang, Lu Zhang, Yue-Ying Mao.

Investigation: Shao-Ting Wang, Ji Li.

Resources: Yue-Ying Mao.

Writing – original draft: Qi-Pu Wang.

Writing – review and editing: Shao-Ting Wang, Ting Zhang, Lu Zhang.

References
[1] Gunluoglu G, Olcmen A, Sokucu SN, et al. Intrapulmonary-located Castleman’s disease, which was surgically resected without pulmonary resection. Ann Thorac Cardiovasc Surg 2011;17:580–3.

[2] Ota H, Kawai H, Matsuo T. Unicentric Castleman’s disease arising from an intrapulmonary lymph node. Case Rep Surg 2013;2013:289089.

[3] Plavnick L, Weiner P, Pevzner S. Amyloidosis in immunoblastic lymphadenopathy. Israel J Med Sci 1980;16:599–603.

[4] Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idopathic multicentric Castleman disease. Blood 2017;129:1646–57.

[5] Kawabata H, Takai K, Kojima M, et al. Castleman-Kojima disease (TAFRO syndrome): a novelsystemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 2013;53:57–61.

[6] Altparmak MR, Pamuk GE, Pamuk ON, et al. Secondary amyloidosis in Castleman’s disease: review of the literature and report of a case. Ann Hematol 2002;81:136–9.

[7] Yamagata N, Fujito J, Hira R, et al. Marked hepatomegaly due to AA type amyloidosis in a case with Castleman’s disease. Int J Hematol 2006;84:70–3.

[8] Takashi I, Junichi H, Tatsuya S, et al. Tocilizumab for AA amyloidosis after treatment of multicentric Castleman Disease with steroids, chemotherapy and rituximab for over 20 years. Intern Med 2015;54:3215–9.

[9] Vinaya G, Hassan T, Kanthi B, et al. Systemic reactive amyloidosis associated with Castleman’s disease. Case Rep Gastroenterol 2013;7:476–81.

[10] Monsnaye HJ, Roelofs HM, van Pelt JF, et al. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 1988;155:112–7.

[11] Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 in Castleman’s lymphoma. Blood 1989;74:1360–7.

[12] Nadir A, Colak N, Koktener A, et al. Isolated intrapulmonary Castleman’s disease: a case report, review of the literature. Ann Thorac Cardiovasc Surg 2014;20 Suppl:689–91.

[13] Lhote R, Haroce J, Duron L, et al. Pulmonary hyalinizing granuloma: a multicenter study of 5 new cases and review of the 135 cases of the literature. Immunol Res 2017;65:375–85.

[14] Shinohara T, Kaneko T, Miyazawa N, et al. Pulmonary hyalinizing granuloma with laryngeal and subcutaneous involvement: report of a case successfully treated with glucocorticoids. Intern Med 2004;43:69–73.

[15] Lien GT, Yang CJ, Yang SF, et al. Pulmonary hyalinizing granuloma mimicking multiple lung metastases: report of fluorodeoxyglucose positron emission findings. J Thorac Imaging 2010;25:W36–9.

[16] Rodriguez-Muguruza S, Holgado S, Olive A. Pulmonary hyalinizing granuloma associated with Sjogren syndrome and ANCA MPO vasculitis. Joint Bone Spine 2015;82:71–2.

[17] Chapman EM, Gown A, Mazzotta R, et al. Pulmonary hyalinizing granuloma with associated elevation in serum and tissue IgG4 occurring in a patient with a history of sarcoidosis. Am J Surg Pathol 2012;36:774–8.

[18] Matsusoka K, Imanishi N, Matsuoka T, et al. Pulmonary hyalinizing granuloma detected in a family member after consanguineous marriage in a patient with a history of sarcoidosis. Am J Surg Pathol 2012;36:774–8.

[19] Matsusoka K, Imanishi N, Matsuoka T, et al. Pulmonary hyalinizing granuloma detected in a family member after confirmation of tuberculosis in his father. Ann Thorac Cardiovasc Surg 2014;20:632–4.

[20] Ahn JH, Kim JS, Cho JH, et al. A first case report of pulmonary hyalinizing granuloma associated with immunoglobulin A nephropathy. Medicine (United States) 2017;96:8–7.

[21] Peiffer K, Mian A, Adebowale A, et al. Radiographic and pathologic manifestations of uncommon and rare pulmonary lesions. Can Assoc Radiol J 2016;67:179–89.

[22] Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. New Engl J Med 2007;356:2361–71.

[23] Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer 1999;85:706–17.